A test by the Australian Racing Forensic Laboratory (ARFL) of samples from a newly prepared batch of Bova’s 100mg/ml injectable omeprazole formulation did not detect testosterone, and Racing New South Wales has now released a statement that the product can continue to be used in racehorses following the guidance of Australian Commonwealth and State legislation.
Nick Bova, managing director of Bova UK, said: "Traces of testosterone in the previous batch were less than one millionth of the internationally accepted standard for impurities.
"Independent experts confirmed that there could be no adverse effects on equine health or equestrian sport, however, we have taken steps to identify and completely eliminate the excipient ingredient that contained traces of testosterone."
Nick added: "Bova can confirm that new batches of this product will not contain the previous trace levels of testosterone and therefore Bova are confident there will be no antidoping issues, no matter what the equestrian pursuit is."
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.